Scilex Holding (D8B0) Stock Overview
Focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
D8B0 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Scilex Holding Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.92 |
| 52 Week High | US$7.68 |
| 52 Week Low | US$6.42 |
| Beta | 1.37 |
| 1 Month Change | 3.02% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -9.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| D8B0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 3.0% | 1.4% | 0.4% |
| 1Y | n/a | 3.1% | -2.6% |
Return vs Industry: Insufficient data to determine how D8B0 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how D8B0 performed against the German Market.
Price Volatility
| D8B0 volatility | |
|---|---|
| D8B0 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in DE Market | 14.4% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: D8B0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine D8B0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 30 | Henry Ji | www.scilexholding.com |
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia.
Scilex Holding Company Fundamentals Summary
| D8B0 fundamental statistics | |
|---|---|
| Market cap | €44.78m |
| Earnings (TTM) | -€325.81m |
| Revenue (TTM) | €34.99m |
Is D8B0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| D8B0 income statement (TTM) | |
|---|---|
| Revenue | US$40.36m |
| Cost of Revenue | US$12.68m |
| Gross Profit | US$27.68m |
| Other Expenses | US$403.52m |
| Earnings | -US$375.83m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -61.34 |
| Gross Margin | 68.59% |
| Net Profit Margin | -931.21% |
| Debt/Equity Ratio | -36.7% |
How did D8B0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/17 23:43 |
| End of Day Share Price | 2026/03/17 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Scilex Holding Company is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Jason Kolbert | D. Boral Capital LLC. |